YAP/TAZ inhibitor-1
Based on 11 publication(s) in Google Scholar
YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC50 of <0.100 μΜ in firefly luciferase assay.
For research use only. We do not sell to patients.
- Purity: 99.72%
- CAS No.: 2093565-23-0
- Formula: C33H39N3O5S2
- Molecular Weight:621.81
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) YAP/TAZ inhibitor-1
More- Nat Biomed Eng. 2025 Nov 3. [Abstract]
- J Extracell Vesicles. 2026 Apr;15(4):e70267. [Abstract]
- Pharmacol Res. 2024 Jun:204:107218. [Abstract]
- Cells. 2021 Oct 26;10(11):2899. [Abstract]
- Int J Mol Sci. 2021 Apr 21;22(9):4322. [Abstract]
- Front Pharmacol. 2020 Aug 27:11:537265. [Abstract]
- Dig Liver Dis. 2024 Jan;56(1):187-197. [Abstract]
- FASEB J. 2025 Aug 15;39(15):e70923. [Abstract]
- Theriogenology. 2025 Oct 15:246:117548. [Abstract]
- bioRxiv. 2026 May 14.
- Research Square Preprint. 2021 Aug.
All YAP Isoforms
More
Biological Activity
|
YAP/TAZ |
YAP and TAZ are transcriptional co-activators of the Hippo pathway network and regulate cell proliferation, migration, and apoptosis. YAP/TAZ inhibitor-1 is an inhibitor of transcriptional coactivator with PDZ binding motif/Yes- associated protein transcriptional coactivator (TAZ/YAP).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2093565-23-0
-
Appearance Solid
-
Molecular Weight 621.81
-
Formula C33H39N3O5S2
-
Color Off-white to yellow
-
SMILES
O=S(C1=CC2=C(C=C1)C3=C(C=C(S(=O)(C4CCC(C)(C)CC4)=O)C=C3)/C2=N\O)(N5CCN(C(C6=CC=CC=C6)C)CC5)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Biomed Eng
Nonexpansive biodegradable matrix promotes blood vessel organoid development for neurovascular repair and functional recovery in ischaemic stroke. [Abstract]2025 Nov 3. PMID: 41184604 -
J Extracell Vesicles
Application of Intracellular Vesicles Surpass Extracellular Vesicles in Regenerative Repair of Inflammatory Bone Defects via the LAMA4-Mediated YAP/TAZ Signalling. [Abstract]2026 Apr;15(4):e70267. PMID: 41885400 -
Pharmacol Res
STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop. [Abstract]2024 Jun:204:107218. PMID: 38768671 -
Cells
Hyaluronan-Based Gel Promotes Human Dental Pulp Stem Cells Bone Differentiation by Activating YAP/TAZ Pathway. [Abstract]2021 Oct 26;10(11):2899. PMID: 34831122 -
Int J Mol Sci
A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma. [Abstract]2021 Apr 21;22(9):4322. PMID: 33919246 -
Front Pharmacol
The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients. [Abstract]2020 Aug 27:11:537265. PMID: 32973536 -
Dig Liver Dis
VEPH1 suppresses the progression of gastric cancer by regulating the Hippo-YAP signalling pathway. [Abstract]2024 Jan;56(1):187-197. PMID: 37244789 -
FASEB J
M2c Macrophages Mediate YAP1 to Promote Vascularized Bone Regeneration in Distraction Osteogenesis. [Abstract]2025 Aug 15;39(15):e70923. PMID: 40788163 -
Theriogenology
Activation of YAP1 and TAZ enhances the in vitro maturation of yak oocytes and influences subsequent embryonic development. [Abstract]2025 Oct 15:246:117548. PMID: 40561881 -
-
Solvent & Solubility
DMSO : 62.5 mg/mL (100.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.02 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6082 mL | 8.0410 mL | 16.0821 mL | 40.2052 mL |
| 5 mM | 0.3216 mL | 1.6082 mL | 3.2164 mL | 8.0410 mL | |
| 10 mM | 0.1608 mL | 0.8041 mL | 1.6082 mL | 4.0205 mL | |
| 15 mM | 0.1072 mL | 0.5361 mL | 1.0721 mL | 2.6803 mL | |
| 20 mM | 0.0804 mL | 0.4021 mL | 0.8041 mL | 2.0103 mL | |
| 25 mM | 0.0643 mL | 0.3216 mL | 0.6433 mL | 1.6082 mL | |
| 30 mM | 0.0536 mL | 0.2680 mL | 0.5361 mL | 1.3402 mL | |
| 40 mM | 0.0402 mL | 0.2010 mL | 0.4021 mL | 1.0051 mL | |
| 50 mM | 0.0322 mL | 0.1608 mL | 0.3216 mL | 0.8041 mL | |
| 60 mM | 0.0268 mL | 0.1340 mL | 0.2680 mL | 0.6701 mL | |
| 80 mM | 0.0201 mL | 0.1005 mL | 0.2010 mL | 0.5026 mL | |
| 100 mM | 0.0161 mL | 0.0804 mL | 0.1608 mL | 0.4021 mL |
YAP/TAZ inhibitor-1 Related Classifications
HY-111429 Related Classifications
Powered by Bioz